BridgeBio Pharma (NASDAQ:BBIO) Releases Earnings Results, Misses Expectations By $0.14 EPS

08 May 2026, 18:47 by Jessica Moore · The Cerbat Gem

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14), FiscalAI reports. The company had revenue of $194.52 million during the quarter, compared to analysts’ expectations of $178.64 million. During the same quarter in the previous year, the company earned ($0.88) EPS. The company’s revenue for the quarter was up 66.8% on a year-over-year basis.

Here are the key takeaways from BridgeBio Pharma’s conference call:

Attruby (acoramidis) delivered $180.6 million in U.S. net product revenue in Q1 (24% QoQ, 392% YoY), with accelerating front‑line share and emerging real‑world evidence showing clinical differentiation versus tafamidis (including reduced diuretic intensification and signals of lower acute kidney injury and mortality).
BridgeBio is preparing three near‑term launches (LGMD2I/BBP‑418, ADH1/encaleret, and achondroplasia/infigratinib) with rapid NDA submission for LGMD2I, active patient‑identification efforts (≈2,000 ADH1 candidates by claims), and strong commercial readiness and early awareness for infigratinib.
The board authorized a $500 million share repurchase program to address a perceived disconnect between intrinsic value and market price, while management says repurchases will be opportunistic and preserve capital for launches and development.
Q1 results show revenue growth (total revenue $194.5M) driven by Attruby, an improving operating loss trajectory (Q1 operating loss $106M, narrowing over recent quarters), and a strong liquidity position ($940.2M in cash and marketable securities) with guidance toward P&L breakeven and sustainable cash flow positivity by and after 2027.

BridgeBio Pharma Stock Down 0.1%

NASDAQ BBIO traded down $0.06 during trading hours on Friday, hitting $67.39. 5,401,164 shares of the company were exchanged, compared to its average volume of 2,774,435. The firm has a market cap of $13.20 billion, a price-to-earnings ratio of -17.83 and a beta of 1.02. The company has a 50 day moving average of $71.27 and a two-hundred day moving average of $71.32. BridgeBio Pharma has a 52-week low of $31.77 and a 52-week high of $84.94.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

Positive Sentiment: BridgeBio reported Q1 revenue of about $194.5 million, beating estimates and showing 66.8% year-over-year growth, helped by continued commercial progress for Attruby. BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
Neutral Sentiment: The company approved inducement grants of restricted stock units for 52 new employees, which supports hiring and retention but also adds modest share-based dilution over time. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral Sentiment: BridgeBio is also drawing attention after a new $500 million ATM program was filed, giving it additional financing flexibility but potentially increasing future share supply. BridgeBio Pharma Launches New $500 Million ATM Program
Negative Sentiment: Despite the revenue beat, Q1 EPS was a loss of $0.84 per share, wider than the $0.70 loss expected, reinforcing concerns that profitability remains elusive. BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Analysts Set New Price Targets

BBIO has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of BridgeBio Pharma in a research report on Monday, April 27th. William Blair started coverage on shares of BridgeBio Pharma in a research note on Tuesday, March 10th. They issued an “outperform” rating for the company. Barclays restated an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Mizuho reaffirmed an “outperform” rating and set a $106.00 target price on shares of BridgeBio Pharma in a research note on Tuesday, April 28th. Finally, Leerink Partners reiterated an “outperform” rating and set a $98.00 target price on shares of BridgeBio Pharma in a report on Thursday, March 12th. Twenty-four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $87.71.

View Our Latest Analysis on BridgeBio Pharma

Insider Buying and Selling at BridgeBio Pharma

In related news, Director Andrea Ellis sold 64,921 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the completion of the transaction, the director owned 18,589 shares in the company, valued at $1,205,868.43. The trade was a 77.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $71.58, for a total transaction of $143,160.00. Following the transaction, the chief accounting officer owned 134,115 shares of the company’s stock, valued at $9,599,951.70. This trade represents a 1.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 239,084 shares of company stock valued at $16,777,579. 14.23% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its stake in BridgeBio Pharma by 23.0% in the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of BridgeBio Pharma by 8.9% during the 4th quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock worth $4,105,000 after acquiring an additional 4,448 shares in the last quarter. XTX Topco Ltd boosted its position in shares of BridgeBio Pharma by 162.4% during the 4th quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock worth $1,007,000 after acquiring an additional 8,150 shares in the last quarter. VARCOV Co. purchased a new position in shares of BridgeBio Pharma in the 4th quarter valued at about $340,000. Finally, Voloridge Investment Management LLC increased its holdings in shares of BridgeBio Pharma by 377.4% in the 4th quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock valued at $48,868,000 after acquiring an additional 505,051 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.